Novartis, Sun Pharma settle dispute over generic Gleevec | business | Hindustan Times
Today in New Delhi, India
Feb 28, 2017-Tuesday
New Delhi
  • Humidity
  • Wind

Novartis, Sun Pharma settle dispute over generic Gleevec

business Updated: May 15, 2014 13:31 IST
Sun Pharmaceutical Industries Ltd


Novartis won a seven-month reprieve from generic competition to its blockbuster leukemia drug Gleevec after reaching a settlement on Thursday with Sun Pharmaceutical Industries Ltd.

Competition from copycat drugs is a major worry for the Basel-based drugmaker, which unveiled a series of deals worth over $25 billion aimed at strengthening its cancer business and exiting underperforming operations last month.

Novartis is looking to plug the hole left by the upcoming expiration of its patent for Gleevec with other treatments, as well as stave off generic competition to the lucrative drug for as long as possible.

Sun, which has tentative approval from the US Food and Drug Administration for a generic version of Gleevec, is the most tangible threat to Novartis' drug.

The drugmaker missed first-quarter sales forecasts last month, blaming a slowdown in sales of the leukemia drug as well as generic competition for Zometa, a bone repair drug.

Under the settlement with Sun, that firm will be allowed to launch a generic version of Gleevec in the United States on February 1, 2016, which gives Novartis seven extra months without the competition from the Indian firm.

"This settlement validates the Novartis patents while allowing Sun Pharma's subsidiary to enter the market with its generic product," Novartis said.

The settlement is mildly positive for Novartis, according to analysts, although investors may have been hoping for a longer delay to Sun's product reaching the market.

"Whilst this settlement might not be as long a delay as some might have hoped for, it nonetheless should provide upside to current expectations," Jefferies analyst Jeffrey Holford said in a note to investors.

Novartis shares traded 0.2% lower at 79.90 Swiss francs following the ruling, compared to a 0.3% rise in a European index of drug stocks.